Board of Directors

An award-winning industry veteran with more than three decades of experience in healthcare, pharmaceuticals, and entrepreneurship, Dr. Frank Douglas leads EOM’s clinical development team. He held leadership roles in both large and small biopharmaceutical companies, leading teams that were responsible for the development and marketing approval of many drugs, including Allegra^®, Lantus^®, Taxotere^®, and Actone^®.

Dr. Douglas has held several academic positions, including Professor of the Practice in the Massachusetts Institute of Technology (MIT) Sloan School of Management and similar appointments in the departments of Biology, Biological Engineering, and the Harvard-MIT Division of Health Sciences and Technology. He also was the founder and first executive director of the MIT Center for Biomedical Innovation and is the recipient of numerous prestigious awards, including being honored twice as the Global Pharmaceutical R&D Director of the Year.

Dr. Douglas holds a BS in Chemistry from Lehigh University, Ph.D. in Physical Chemistry, and a M.D. from Cornell University.

Eli Goldberger is EOM’s Founder, Chairman and Chief Operating Officer. Mr. Goldberger is a successful entrepreneur, focusing on advancing innovations in pharmaceuticals, women’s health, and energy.

Dr. Irach Taraporewala, EOM CEO and Director, has multiple accomplishments in drug discovery, development and delivery, formulation, medical devices, radiopharmaceuticals, DNA diagnostics, and regulatory affairs. His R&D contributions span several therapeutic areas, including ophthalmology, cancer, inflammation, immunology, endocrine, CNS, infectious disease, malaria, and cachexia. Dr. Taraporewala also was the founder, CEO, President, and Board member of OHR Pharmaceutical.

Julie Kampf was elected to the Company’s board of directors in April 2022. Ms. Kampf is Chief Executive Officer of JBK Associates International, a global executive search firm which she founded in 2003. Prior thereto, she gained deep business knowledge in product development, marketing, sales, and organizational development, having started her 17-year career in the fashion industry as a Macy’s Executive Trainee, with a subsequent series of roles of increasing responsibility at Warnaco Inc, Hartmann Inc and Michael Stevens, LTD, ultimately rising to Sr. VP. She has served as a member of the board of directors of Marizyme, Inc., a publicly traded biotechnology company, since February 2021., and as a member of the board of directors of Jupiter Neurosciences, Inc. since September 2021.

Ms. Kampf also has extensive not-for-profit board and advisory committee experience having served on Howard University’s School of Communications Board of Visitors, where she helped launch an entrepreneurial incubator and established an award for student entrepreneurs. Her not-for-profit board service spans the Linkage Diversity Summit, Enterprising Women magazine, International Association of Corporate and Professional Recruitment, Girl Scout Council of Bergen County, Guiding Eyes for the Blind. Additionally, she has served on the Executive Committee of Good Grief, a national leader in delivering grief services to children and their families. Ms. Kampf earned a BA in Political Science from the University of Rhode Island, where she minored in Marketing.

Robert W. Lehman was elected to our Board of Directors in April 2022. From 1995 until his retirement in 2021, he was a partner at Ernst & Young, LLP where he served as the lead audit partner and quality review partner for dozens of SEC reporting companies. During the most recent ten years, he acted as that firm’s US Division and Market Leader for the East Coast Real Estate, Hospitality and Construction Practice. Mr. Lehman holds a B.A. in Accounting from Queens College of the City University of New York.